Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
10 avr. 2024 07h00 HE
|
Crescendo Biologics
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Preclinical data demonstrate strong rationale for...
Non-Executive Director Appointment
30 sept. 2021 07h00 HE
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation...
Non-Executive Director Appointment
30 sept. 2021 02h02 HE
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation...